NEW YORK, July 15, 2015 /PRNewswire/ -- Stull, Stull &
Brody (www.ssbny.com) is investigating potential claims on behalf
of shareholders of Receptos, Inc. (NASDAQ: RCPT) ("Receptos" or the
"Company") concerning whether the Company's Board of Directors
breached its fiduciary duty by entering into an agreement and plan
of merger under which all of the Company's outstanding shares will
be acquired by Celgene Corporation for $232.00 per share in cash.
The current investigation is focused upon whether the Company's
Board of Directors breached its fiduciary duty to maximize value to
the Company's shareholders and to act in shareholders' best
interests, including whether the Board of Directors undertook an
adequate sales process and disclosed all material information to
the Company's shareholders.
While the terms of the proposed transaction provide that the
Company's shareholders will receive $232.00 per share in cash, at least one analyst
has set a target price of $348.00 per
share for the Company's stock.
Shareholders of Receptos may contact Jason D'Agnenica, Esq. at
Stull, Stull & Brody to discuss their rights in connection with
the proposed transaction by calling 1-800-337-4983, extension 145,
or by email at receptos@ssbny.com.
Stull, Stull & Brody has represented shareholders in merger
litigation and other securities class actions for over 40 years and
has obtained court approval of substantial settlements on numerous
occasions.
Attorney Advertising. Prior Results Do Not Guarantee a
Similar Outcome.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/stull-stull--brody-launches-investigation-into-possible-breaches-of-fiduciary-duty-by-the-board-of-directors-of-receptos-inc-300113704.html
SOURCE Stull, Stull & Brody